Ovarian Cancer Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Mario Negri Institute, Tesaro, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme, Gradalis, Inc., AGO Research GmbH, Haider Mahdi, AstraZeneca, Jacobio Pharmaceuticals, S

DelveInsight's "Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ovarian Cancer, historical and forecasted epidemiology as well as the Ovarian Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ovarian Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ovarian Cancer Market Forecast
https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ovarian Cancer Market Report:
• The Ovarian Cancer market size was valued ~USD 2,700 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2025, Corcept Therapeutics Incorporated has announced the initiation of BELLA, a Phase 2 clinical trial designed to assess the safety and effectiveness of a treatment combination-relacorilant with nab-paclitaxel and Avastin (bevacizumab)-in patients with platinum-resistant ovarian cancer.
• In March 2025, US-based pharmaceutical company AbbVie has shared the final analysis from the Phase III MIRASOL trial, which evaluated its antibody-drug conjugate (ADC), Elahere, against chemotherapy in the treatment of platinum-resistant ovarian cancer (PROC). The randomized trial focused on the safety and efficacy of the therapy in women with folate receptor alpha (FRα) positive PROC. The primary endpoint of the trial was progression-free survival (PFS), while secondary endpoints included objective response rate (ORR) and overall survival (OS).
• In March 2025, Imunon announced that the US Food and Drug Administration (FDA) has aligned with the Phase III OVATION 3 trial protocol for IMNN-001, its lead candidate for treating ovarian cancer. IMNN-001 is being developed for women with newly diagnosed advanced ovarian cancer. The company is in the process of initiating clinical trial sites and working with investigators to begin enrolling participants.
• In February 2025, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib-a unique dual PARP/Wnt pathway inhibitor-has announced its plans to advance the clinical development of stenoparib towards FDA approval for advanced ovarian cancer. Utilizing its proprietary Drug Response Predictor (DRP®) technology for personalized treatment, the company aims to expand on existing Phase 2 trial data to optimize stenoparib dosing and refine the DRP® patient selection criteria to enhance clinical outcomes.
• In October 2024, Oncoinvent initiated dosing in its Phase II clinical trial of Radspherin, an alpha-emitting radiation therapy, targeting peritoneal carcinomatosis stemming from ovarian cancer. This randomized, controlled study aims to evaluate the safety and effectiveness of the treatment. The trial's main objective is to compare progression-free survival between patients treated with Radspherin after surgery and those who receive only pre-operative chemotherapy followed by surgery.
• According to DelveInsight's estimate, the total diagnosed incident cases of ovarian cancer in the 7MM were approximately 57,000 cases in 2023. It is projected that these cases will decrease to about 42,000 by 2034.
• According to DelveInsight's estimates, among the EU4 and the UK, Germany had the highest number of total diagnosed incident cases of ovarian cancer, with approximately 6,400 cases in 2023. This number is expected to decrease to around 4,600 cases by 2034.
• In 2023, the total number of treated cases of ovarian cancer in the US included approximately 15,600 for first-line treatment, 10,000 for second-line treatment, 6,900 for third-line treatment, and 4,600 for fourth-line or higher treatments.
• In 2023, the total number of age-specific cases of ovarian cancer in the US were approximately 280 for those under 20 years old, 2,300 for ages 20-44, 8,100 for ages 45-64, 7,800 for ages 65-84, and 1,400 for those aged 85 and older. These numbers are expected to decrease during the study period from 2020 to 2034.
• According to the Centers for Disease Control and Prevention (CDC) (2022), ovarian cancer is a group of diseases that starts in the ovaries, fallopian tubes, or peritoneum, collectively accounting for only 3% of cancers diagnosed in women.
• Key Ovarian Cancer Companies: Mario Negri Institute, Tesaro, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme, Gradalis, Inc., AGO Research GmbH, Haider Mahdi, AstraZeneca, Jacobio Pharmaceuticals, SpringWorks Therapeutics, Takeda, Suzhou Suncadia Biopharmaceutical, EMD Serono Research, Hoffmann-La Roche, Anhui Provincial Cancer Hospital, Jiangsu Simcere Pharmaceutical, and others
• Key Ovarian Cancer Therapies: Olaparib, Niraparib, MORAb-202, Paclitaxel, Vigil, olaparib, Pembrolizumab, Olaparib, JAB-8263, Nirogacestat, TAK-853, SHR-A1921, Tuvusertib (M1774), Ipatasertib, Paclitaxel, BD0801, and others
• The Ovarian Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ovarian Cancer pipeline products will significantly revolutionize the Ovarian Cancer market dynamics.

Ovarian Cancer Overview
Ovarian cancer is a type of cancer that begins in the ovaries, which are part of the female reproductive system. It's the fifth most common cancer among women and is often referred to as the "silent killer" because symptoms may not appear until the disease has progressed to an advanced stage.

Get a Free sample for the Ovarian Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ovarian Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ovarian Cancer Epidemiology Segmentation:
The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Diagnosed Incident Cases of Ovarian Cancer in the 7MM
• Age-specific Cases of Ovarian Cancer in the 7MM
• Type-specific Cases of Ovarian Cancer in the 7MM
• Stage-specific Cases of Ovarian Cancer in the 7MM
• Line-wise Treated Cases of Ovarian Cancer in the 7MM

Download the report to understand which factors are driving Ovarian Cancer epidemiology trends @ Ovarian Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ovarian Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ovarian Cancer market or expected to get launched during the study period. The analysis covers Ovarian Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ovarian Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ovarian Cancer Therapies and Key Companies
• Olaparib: Mario Negri Institute
• Niraparib: Tesaro, Inc.
• MORAb-202: Bristol-Myers Squibb
• Paclitaxel: Merck Sharp & Dohme
• Vigil: Gradalis, Inc.
• olaparib: AGO Research GmbH
• Pembrolizumab: Haider Mahdi
• Olaparib: AstraZeneca
• JAB-8263: Jacobio Pharmaceuticals
• Nirogacestat: SpringWorks Therapeutics
• TAK-853: Takeda
• SHR-A1921: Suzhou Suncadia Biopharmaceutical
• Tuvusertib (M1774): EMD Serono Research
• Ipatasertib: Hoffmann-La Roche
• Paclitaxel: Anhui Provincial Cancer Hospital
• BD0801: Jiangsu Simcere Pharmaceutical

Discover more about therapies set to grab major Ovarian Cancer market share @ Ovarian Cancer Treatment Landscape
https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ovarian Cancer Market Strengths
• Advocacy bodies like the International Gynecologic Cancer Society (IGCS) and the World Ovarian Cancer Coalition (WOCC) have developed initiatives to raise awareness and educate women about ovarian cancer. These programs disseminate knowledge on risk factors, symptoms, recommended screening, and prevention strategies to help better manage ovarian cancer.

Ovarian Cancer Market Opportunities
• Increasing prevalence due to an increase in the aging population and improved patient survival.
• Rapid advancement in R&D will cater to the lack of early stage diagnosis; hence, more patient pool will be available for clinical studies and treatment.

Scope of the Ovarian Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ovarian Cancer Companies: Mario Negri Institute, Tesaro, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme, Gradalis, Inc., AGO Research GmbH, Haider Mahdi, AstraZeneca, Jacobio Pharmaceuticals, SpringWorks Therapeutics, Takeda, Suzhou Suncadia Biopharmaceutical, EMD Serono Research, Hoffmann-La Roche, Anhui Provincial Cancer Hospital, Jiangsu Simcere Pharmaceutical, and others
• Key Ovarian Cancer Therapies: Olaparib, Niraparib, MORAb-202, Paclitaxel, Vigil, olaparib, Pembrolizumab, Olaparib, JAB-8263, Nirogacestat, TAK-853, SHR-A1921, Tuvusertib (M1774), Ipatasertib, Paclitaxel, BD0801, and others
• Ovarian Cancer Therapeutic Assessment: Ovarian Cancer current marketed and Ovarian Cancer emerging therapies
• Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement

To know more about Ovarian Cancer companies working in the treatment market, visit @ Ovarian Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Ovarian Cancer Market Report Introduction
2. Executive Summary for Ovarian Cancer
3. SWOT analysis of Ovarian Cancer
4. Ovarian Cancer Patient Share (%) Overview at a Glance
5. Ovarian Cancer Market Overview at a Glance
6. Ovarian Cancer Disease Background and Overview
7. Ovarian Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Ovarian Cancer
9. Ovarian Cancer Current Treatment and Medical Practices
10. Ovarian Cancer Unmet Needs
11. Ovarian Cancer Emerging Therapies
12. Ovarian Cancer Market Outlook
13. Country-Wise Ovarian Cancer Market Analysis (2020-2034)
14. Ovarian Cancer Market Access and Reimbursement of Therapies
15. Ovarian Cancer Market Drivers
16. Ovarian Cancer Market Barriers
17. Ovarian Cancer Appendix
18. Ovarian Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Ovarian Cancer Pipeline https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Ovarian Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ovarian Cancer market. A detailed picture of the Ovarian Cancer pipeline landscape is provided, which includes the disease overview and Ovarian Cancer treatment guidelines.

Ovarian Cancer Epidemiology https://www.delveinsight.com/report-store/ovarian-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ovarian Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Ovarian Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.